Where Do the Immune Checkpoint Inhibitors Stand in the Management of Triple Negative Breast Cancer?

Immunotherapy - United Kingdom
doi 10.2217/imt-2017-0171
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Checkpoint Inhibitors in Triple-Negative Breast Cancer (TNBC): Where to Go From Here

Cancer
Cancer ResearchOncology
2018English

Immune Checkpoint Inhibitors: A Step Forward in Cancer Management

Madridge Journal of Oncogenesis
2019English

Gene Expression Profiling Identified TP53MutPIK3CAWild as a Potential Biomarker for Patients With Triple‑negative Breast Cancer Treated With Immune Checkpoint Inhibitors

Oncology Letters
Cancer ResearchOncology
2020English

Nab-Paclitaxel for the Management of Triple-Negative Metastatic Breast Cancer

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2015English

Triple-Negative Breast Cancer

2018English

How Many Diseases Is Triple Negative Breast Cancer: The Protagonism of the Immune Microenvironment

ESMO Open
Cancer ResearchOncology
2017English

Triple Negative Breast Cancer: Breast Cancer Research in Evolution

Breast Disease
MedicineCancer ResearchOncology
2011English

Immune Checkpoint Inhibitors for Metastatic Bladder Cancer

Cancer Treatment Reviews
MedicineOncologyRadiologyNuclear MedicineImaging
2018English

The Clinical Promise of Immunotherapy in Triple-Negative Breast Cancer

Cancer Management and Research
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy